Nitin Jain, MD. Associate Professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
Nitin Jain, MD delved into the intricacies of T-cell Acute Lymphoblastic Leukemia (T-ALL). He highlighted the pressing medical void in this area and underscored the advent of innovative therapies. In particular, he focused on Chimeric Antigen Receptor T-cell (CAR-T) therapies, which hold immense promise for patients.
REGISTER NOW TO JOIN US AT THESE UPCOMING EVENTS
AML-ALL US – Online content available – https://aml-allus2023.md-education.com/register/
AML-ALL EU – Registration open – https://aml-alleu2023.md-education.com/register/
MPN-MDS EU – registration open – https://mpn-mdseu2023.md-education.com/register/
A significant segment of the discussion revolved around the emergence of CD7 CARs and their potential impact on patients. Additionally, Nitin Jain, MD shared insights into novel approaches targeting the enzyme LCK, which is overexpressed in a substantial portion of T-ALL cases.